Publications
44
Citations
180
Est. group size
~17
Recurring co-author estimate
Active years
10
Publishing since 2017
Kieran Sahasrabudhe's research focuses on acute myeloid leukemia (AML), a cancer of blood-forming cells, with particular attention to treatment options for older patients, real-world outcomes data, and emerging targeted drugs. Work includes multicenter studies (e.g., the MARROW consortium) comparing chemotherapy intensities and newer agents like venetoclax, CPX-351, and menin inhibitors, as well as reviews on monitoring disease after treatment (measurable residual disease) and immunotherapy for leukemia. Publications also touch on acute lymphoblastic leukemia and stem cell transplantation topics.
Publication output was low and sporadic through the mid-2010s, dipped in 2019, then grew unevenly from 2020 onward, with a notable increase in 2025, suggesting an overall growing trend in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Post-Transplant Outcomes in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with VEN/HMA vs 7+3: A Real-World, Multicenter Analysis From the MARROW Consortium
Transplantation and Cellular Therapy · 2026
- Immunotherapy for Acute Leukemia
2025
- Real‐world analysis of <scp>CPX</scp> ‐351 in <scp>AML</scp> ‐ <scp>MR</scp> : A multicentre study from the <scp>MARROW</scp> consortium
British Journal of Haematology · 2025
- A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium
Blood · 2025
- Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
Journal of Hematology & Oncology · 2024
- MRD in AML: who, what, when, where, and how?
Blood · 2024
- Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias
Expert Review of Hematology · 2023
- Case report: Sustained complete remission with ivosidenib in a patient with relapsed, IDH1-mutated acute leukemia
Frontiers in Hematology · 2023
- Novel investigational approaches for high-risk genetic subsets of AML: <i>TP53</i>, <i>KMT2A</i>, <i>FLT3</i>
Hematology · 2022
- Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapy
Frontiers in Oncology · 2022
- Survival and Post-Transplant Outcomes in Acute Myeloid Leukemia (AML) Patients Aged 60-75 Treated with High Intensity Chemotherapy (HiC) Vs Low Intensity Targeted Therapy (LITT)
Transplantation and Cellular Therapy · 2022
- Venetoclax and acute myeloid leukaemia: an expanding new frontier
The Lancet Haematology · 2022
- Immunotherapy for Acute Leukemia
2022
- <p>Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy</p>
Blood and Lymphatic Cancer Targets and Therapy · 2020
- TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data
Leukemia & lymphoma/Leukemia and lymphoma · 2018
- Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature×13
- Blood×10
- Journal of Clinical Oncology×2
- Transplantation and Cellular Therapy×2
- Frontiers in Hematology×2
- Melanie Rebechi
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
- Alice S. Mims
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile